PEPHA
Pepper Residential Securities Trust No. 39
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Class A1-A Frn Mat 16-Jul-2065 Min Cons $5Ht Nc
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PEPHA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PEPHA
N/A
PEPHA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in PEPHA also invest in...
Want more shares? Try these...
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
🙌 Performance (5Yr p.a)
-2.79%
📊 Share price
$0.07 AUD
📦 LOGISTICS
Phoslock Environmental Technologies Ltd. is a global water technology company which engages in the manufacture and sale of environmental solutions. The firm is specialized in engineering solutions and water treatment products to remediate polluted lakes, rivers, canals and drinking water reservoirs. The company has four operating segments based on geographical areas, such as Australia/NZ, Europe/The United Kingdom, United States/Canada/Brazil, and China. The Company’s products include Phoslock and Phosflow. Phoslock is a proprietary water treatment product that permanently binds excess phosphorus in the water column and sediments and enables it to settle in an environmentally benign state. Along with Phoslock, the Company also supplies zeolites and specialized solutions that address water pollution issues. Phosflow absorbs phosphorus from water upon contact. Phosflow is used in wastewater effluents including municipal, industrial, and agricultural wastewaters. Phosflow can be packaged into various vessels and chambers, as well as water permeable containers.
🙌 Performance (5Yr p.a)
-19.47%
📊 Share price
$0.03 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
Peak Rare Earths Ltd. engages in the exploration and development of mineral properties primarily rare earth and gold deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-11-29. The firm is focused on delivering its high-grade Ngualla rare earth project to enable low carbon technologies to power green transformation. The Ngualla Project is a rare earth development located near the Ngwala Village and approximately 150 kilometers (km) from the City of Mbeya in the Songwe Region and on the edge of the East African Rift Valley. The Ngualla Project SML has initially been granted over the original SML application area of approximately 18.14 square kilometers (km2). Under the Framework Agreement, the Government of Tanzania has undertaken to expand the SML area to include an existing prospecting license (PL 10897/2016) and a recently expired prospecting license (PL 9157/2013), which would increase the SML area to approximately 54.64 km2.
🙌 Performance (5Yr p.a)
-15.33%
📊 Share price
$0.10 AUD
⛏️ MINING
Peninsula Energy Ltd. engages in the mining, exploration, and development of uranium properties. The company is headquartered in Subiaco, Western Australia. The firm owns the Lance Project (Lance) and Dagger Project. The Lance Project is located in Wyoming, United States of America, operated through its 100% owned subsidiary, Strata Energy Inc (Strata). The Lance Projects comprise the Ross Production Project Area, Kendrick Development Project Area and Barber Exploration Area. The Lance Projects are located in Crook County, in northeastern Wyoming, approximately 31 miles east-northeast of the town of Gillette and extend over a strike length of 37 kilometers (kms) to the north, and over a strike width of eight km. The company holds mineral rights and surface access rights over a non-contiguous north-south distance of about 50 km. The company has mineral rights over 34,068 acres and surface access rights over land holdings 8,426 acres. The Dagger Project in Crook County, Wyoming lies within the North Black Hills district in the northeast corner of the state.
🙌 Performance (5Yr p.a)
-13.52%
📊 Share price
$0.06 AUD
⚡️ ENERGY